Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with ...
Reported positive data updates from its ongoing Phase 2a trial of lead program IMM-1-104, including encouraging responses in combination with chemotherapy in first-line pancreatic cancer - - Announced ...
Eli Lilly and Company today announced that preclinical data for agents targeting SMARCA2 (BRM) and multiple KRAS mutations will be presented at the American Association for Cancer Research (AACR) ...
Verastem Oncology , a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, announced today multiple oral and poster presentations at the ...
In a $780 million deal, Servier is obtaining global rights to develop and commercialize BDTX-4933 in multiple solid tumors with RAS or RAF mutations.
Identification of biomarkers and target drugs for melanoma: a topological and deep learning approach
and BRAF and NRAS mutation status. Samples were stratified into two groups based on pathological diagnosis: melanocytic nevi (n = 23) and melanoma (n = 57). Previous studies often identified several ...
Mutations in other RAS genes also contribute to human cancers, for example, NRAS mutations are common in melanoma, while HRAS mutations frequently occur in head and neck cancers. Amplification and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback